Citadel Advisors
MRVI icon

Citadel Advisors’s Maravai LifeSciences MRVI Stock Holding History

Citadel Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$215K Sell
76,000
-74,700
-50% -$253K ﹤0.01% 11272
2025
Q4 		$490K Sell
150,700
-5,900
-4% -$19.9K ﹤0.01% 9070
2025
Q3 		$449K Buy
156,600
+32,300
+26% +$82.5K ﹤0.01% 9400
2025
Q2 		$300K Buy
124,300
+80,300
+183% +$169K ﹤0.01% 9832
2025
Q1 		$97.2K Sell
44,000
-16,500
-27% -$65.2K ﹤0.01% 11516
2024
Q4 		$330K Buy
60,500
+21,400
+55% +$138K ﹤0.01% 9455
2024
Q3 		$325K Buy
39,100
+17,300
+79% +$150K ﹤0.01% 9168
2024
Q2 		$156K Buy
21,800
+7,000
+47% +$60.4K ﹤0.01% 10289
2024
Q1 		$128K Buy
14,800
+14,600
+7,300% +$98.8K ﹤0.01% 11006
2023
Q4 		$1.31K Sell
200
-3,500
-95% -$22.6K ﹤0.01% 13849
2023
Q3 		$37K Sell
3,700
-17,900
-83% -$197K ﹤0.01% 12085
2023
Q2 		$268K Sell
21,600
-16,000
-43% -$216K ﹤0.01% 9283
2023
Q1 		$527K Buy
37,600
+5,100
+16% +$73.2K ﹤0.01% 8196
2022
Q4 		$465K Sell
32,500
-24,500
-43% -$386K ﹤0.01% 8392
2022
Q3 		$1.46M Sell
57,000
-37,500
-40% -$941K ﹤0.01% 6212
2022
Q2 		$2.69M Sell
94,500
-18,900
-17% -$599K ﹤0.01% 4964
2022
Q1 		$4M Buy
113,400
+32,300
+40% +$1.08M ﹤0.01% 4611
2021
Q4 		$3.4M Sell
81,100
-4,100
-5% -$166K ﹤0.01% 5101
2021
Q3 		$4.18M Buy
85,200
+50,000
+142% +$2.44M ﹤0.01% 4647
2021
Q2 		$1.47M Buy
35,200
+7,700
+28% +$298K ﹤0.01% 7358
2021
Q1 		$980K Buy
27,500
+17,000
+162% +$563K ﹤0.01% 8168
2020
Q4 		$295K Buy
+10,500
New +$292K ﹤0.01% 9107

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's MRVI Position: Q1 2026 in Review

Citadel Advisors increased its Maravai LifeSciences (MRVI) stake by 140% in Q1 2026, buying an estimated $2.94M and bringing the position to 1,484,319 shares worth $4.2M. The position accounts for ﹤0.01% of the portfolio, ranked #4631.

Citadel Advisors first reported a position in MRVI in Q4 2020 and has held it in 21 quarters since. The position peaked at $64.7M in Q3 2021. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Citadel Advisors held 1,484,319 shares of Maravai LifeSciences worth $4.2M as of Q1 2026.
  • Citadel Advisors bought 866,865 Maravai LifeSciences shares in Q1 2026, an estimated $2.94M.
  • Maravai LifeSciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4631 holding.
  • Citadel Advisors first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 21 quarters since.
  • Citadel Advisors's Maravai LifeSciences position peaked at $64.7M in Q3 2021.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.